Summary
36.33 1.25(3.55%)10/04/2024
Baxter International Inc. (BAX)
Baxter International Inc. (BAX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.55 | -6.62 | -3.18 | 3.89 | -14.79 | -1.72 | -55.19 | 2,388.01 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 36.33 | |
| Open | 35.25 | |
| High | 36.37 | |
| Low | 34.94 | |
| Volume | 4,220,741 | |
| Change | 1.25 | |
| Change % | 3.55 | |
| Avg Volume (20 Days) | 2,997,786 | |
| Volume/Avg Volume (20 Days) Ratio | 1.41 | |
| 52 Week Range | 31.01 - 44.01 | |
| Price vs 52 Week High | -17.46% | |
| Price vs 52 Week Low | 17.14% | |
| Range | 3.05 | |
| Gap Up/Down | -0.77 | |
Fundamentals | ||
| Market Capitalization (Mln) | 19,749 | |
| EBIDTA | 2,872,000,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 1.6956 | |
| WallStreet Target Price | 43.83 | |
| Book Value | 16.0390 | |
| Earnings Per Share | -0.0800 | |
| EPS Estimate Current Quarter | 0.6100 | |
| EPS Estimate Next Quarter | 0.6700 | |
| EPS Estimate Current Year | 2.9100 | |
| EPS Estimate Next Year | 3.2300 | |
| Diluted EPS (TTM) | -0.0800 | |
| Revenues | ||
| Profit Marging | 0.1779 | |
| Operating Marging (TTM) | 0.1005 | |
| Return on asset (TTM) | 0.0354 | |
| Return on equity (TTM) | -0.0042 | |
| Revenue TTM | 14,892,000,256 | |
| Revenue per share TTM | 29.3870 | |
| Quarterly Revenue Growth (YOY) | 0.0220 | |
| Quarterly Earnings Growth (YOY) | -0.1970 | |
| Gross Profit (TTM) | 6,031,000,000 | |
| Dividends | ||
| Dividend Share | 1.1600 | |
| Dividend Yield | 0.0325 | |
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 13.9082 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.4449 | |
| Revenue Enterprise Value | 2.1408 | |
| EBITDA Enterprise Value | 18.9665 | |
| Shares | ||
| Shares Outstanding | 509,580,000 | |
| Shares Float | 507,139,301 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.03 | |
| Insider (%) | 0.38 | |
| Institutions (%) | 92.80 | |
10/04 08:11 EST - zacks.com
Reasons to Add Baxter International Stock to Your Portfolio Now
BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Reasons to Add Baxter International Stock to Your Portfolio Now
BAX's robust growth across all regions, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
10/03 10:47 EST - zacks.com
Here's Why Baxter International (BAX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Baxter International (BAX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
10/02 12:46 EST - zacks.com
BAX vs. LMAT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
BAX vs. LMAT: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
10/02 10:46 EST - zacks.com
Are Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
10/01 08:00 EST - forbes.com
Does Baxter Stock Offer Any Room For Growth?
Baxter stock (NYSE: BAX), a healthcare company, currently trades at $38 per share, more than 50% lower than the level seen in February 2022. BAX stock has fared worse than its peer – Becton, Dickinson & Company stock, down 7% over this period.
Does Baxter Stock Offer Any Room For Growth?
Baxter stock (NYSE: BAX), a healthcare company, currently trades at $38 per share, more than 50% lower than the level seen in February 2022. BAX stock has fared worse than its peer – Becton, Dickinson & Company stock, down 7% over this period.
09/30 18:07 EST - benzinga.com
Hurricane Helene Shutters Baxter International's Key Manufacturing Hub In North Carolina
Baxter International Inc BAX. has shut down its largest manufacturing facility following significant damage caused by Hurricane Helene.
Hurricane Helene Shutters Baxter International's Key Manufacturing Hub In North Carolina
Baxter International Inc BAX. has shut down its largest manufacturing facility following significant damage caused by Hurricane Helene.
09/30 10:45 EST - zacks.com
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
Baxter Shares May Gain on the Launch of Its Latest Vest APX System
BAX launches its next-generation airway clearance system, The Vest APX System, for chronic lung conditions.
09/29 16:00 EST - businesswire.com
Baxter Provides Update on North Cove, N.C., Facility and Hurricane Helene Relief Plans for Community
DEERFIELD, Ill.--(BUSINESS WIRE)---- $BAX--Baxter International Inc. (NYSE:BAX), a global medtech leader, today shared updates regarding the impact of Hurricane Helene, which brought unprecedented rain and extensive flooding to Western North Carolina, on the operations of its North Cove facility in Marion, N.C. Baxter's North Cove site was affected by flooding due to the storm and is currently closed for production. The company is working around the clock in close coordination with local, state and fede.
Baxter Provides Update on North Cove, N.C., Facility and Hurricane Helene Relief Plans for Community
DEERFIELD, Ill.--(BUSINESS WIRE)---- $BAX--Baxter International Inc. (NYSE:BAX), a global medtech leader, today shared updates regarding the impact of Hurricane Helene, which brought unprecedented rain and extensive flooding to Western North Carolina, on the operations of its North Cove facility in Marion, N.C. Baxter's North Cove site was affected by flooding due to the storm and is currently closed for production. The company is working around the clock in close coordination with local, state and fede.
09/26 07:30 EST - businesswire.com
Baxter Launches Next Generation of The Vest System for Airway Clearance
BOSTON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort and add.
Baxter Launches Next Generation of The Vest System for Airway Clearance
BOSTON--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort and add.
09/24 09:11 EST - zacks.com
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
4 Medical Product Stocks to Buy From a Prospective Industry
Ongoing rise in demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, BAX, HAE and PAHC are well-poised to gain from the favorable factors.
09/19 07:00 EST - seekingalpha.com
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.
5 Incredible Healthcare High-Yield Blue-Chip Bargain Buys For 2025
Healthcare is undervalued despite being the top sector for earnings growth, making it an attractive investment with solid fundamentals and the potential for explosive returns in 2025. Investing in healthcare ETFs or individual undervalued healthcare stocks can capitalize on the sector's recovery and expected double-digit growth through 2026. Screening for blue-chip healthcare stocks with solid fundamentals and fair valuations can yield superior returns, including these five coiled spring blue chips.
09/16 13:05 EST - zacks.com
Baxter (BAX) Upgraded to Buy: Here's Why
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter (BAX) Upgraded to Buy: Here's Why
Baxter (BAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
09/16 12:46 EST - zacks.com
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
BAX vs. PODD: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
09/16 10:47 EST - zacks.com
Is Baxter International (BAX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Baxter International (BAX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
09/13 04:00 EST - seekingalpha.com
Broyhill's Q2 2024 Top Five Investments
Our top five investments—Avantor, Baxter, Fiserv, Nintendo, and Philip Morris—represented 50% of the equity portfolio, with mixed performance during the quarter. Avantor's shares rallied 26% in July after a strong earnings report, reaffirming full-year guidance and showing signs of industry recovery. Baxter's shares increased significantly post-earnings, demonstrating portfolio durability and organic growth, prompting us to accumulate shares at attractive valuations.
Broyhill's Q2 2024 Top Five Investments
Our top five investments—Avantor, Baxter, Fiserv, Nintendo, and Philip Morris—represented 50% of the equity portfolio, with mixed performance during the quarter. Avantor's shares rallied 26% in July after a strong earnings report, reaffirming full-year guidance and showing signs of industry recovery. Baxter's shares increased significantly post-earnings, demonstrating portfolio durability and organic growth, prompting us to accumulate shares at attractive valuations.
09/09 09:00 EST - businesswire.com
Baxter Appoints Jeffrey A. Craig to Its Board
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. “We are excited to welcome Jay to Baxter's board,” said José (Joe) E. Almeida, chair.
Baxter Appoints Jeffrey A. Craig to Its Board
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter's Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12. “We are excited to welcome Jay to Baxter's board,” said José (Joe) E. Almeida, chair.
09/03 07:30 EST - globenewswire.com
Spectral Medical Provides August Tigris Trial Update
Management provides view on recently announced Vantive-Carlyle Group transaction Management provides view on recently announced Vantive-Carlyle Group transaction
Spectral Medical Provides August Tigris Trial Update
Management provides view on recently announced Vantive-Carlyle Group transaction Management provides view on recently announced Vantive-Carlyle Group transaction
08/27 10:31 EST - zacks.com
Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Baxter International (BAX) is looking like an interesting pick, as it just reached a key level of support. BAX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Baxter International (BAX) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Baxter International (BAX) is looking like an interesting pick, as it just reached a key level of support. BAX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
08/19 16:15 EST - forbes.com
Baxter To Sell Its Kidney Care Unit To Carlyle For $3.8 Billion
On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG) announced that they have signed a definitive agreement under which Carlyle will acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion (For details refer to spinoffresearch.com). Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated to be approximately $3 billion.
Baxter To Sell Its Kidney Care Unit To Carlyle For $3.8 Billion
On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG) announced that they have signed a definitive agreement under which Carlyle will acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion (For details refer to spinoffresearch.com). Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated to be approximately $3 billion.
08/17 09:00 EST - seekingalpha.com
10 Great Dividend Stocks For The Next 10 Years
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and easy-to-implement filtering method to narrow down our list to probable candidates. In our view, these dividend stocks will provide sustainable yields with decent dividend growth that will likely meet and exceed the rate of inflation.
10 Great Dividend Stocks For The Next 10 Years
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and easy-to-implement filtering method to narrow down our list to probable candidates. In our view, these dividend stocks will provide sustainable yields with decent dividend growth that will likely meet and exceed the rate of inflation.